Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, open-label, multiple-dose, dose escalation study to investigate the pharmacokinetics, efficacy, and safety of rVIIa-FP (CSL689) in subjects with hemophilia (A or B) and inhibitors

Next Previous
Trial Profile

A multicenter, open-label, multiple-dose, dose escalation study to investigate the pharmacokinetics, efficacy, and safety of rVIIa-FP (CSL689) in subjects with hemophilia (A or B) and inhibitors

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 12 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CSL 689 (Primary) ; Eptacog alfa
  • Indications Haemophilia A; Haemophilia B
  • Focus Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors CSL Behring

Most Recent Events

  • 23 Apr 2018 Status changed from active, no longer recruiting to discontinued due to business decision non safety related.
  • 09 Feb 2018 Planned End Date changed from 8 Nov 2019 to 21 Jun 2018.
  • 09 Feb 2018 Planned primary completion date changed from 25 Oct 2019 to 18 May 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top